Company news

Corbus Pharmaceuticals Holdings, Inc. news in 2024

Corbus Pharmaceuticals Holdings, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

December 8, 2024

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

December 2, 2024

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

November 6, 2024

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

November 3, 2024

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

October 15, 2024

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

August 19, 2024

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

August 5, 2024

Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 6, 2024

Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting

April 23, 2024

Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

April 1, 2024

Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

March 11, 2024

Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

February 27, 2024

Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares

February 1, 2024

Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)

January 8, 2024

Decks in 2024